all report title image

TRIGEMINAL NEURALGIA TREATMENT MARKET ANALYSIS

Trigeminal Neuralgia Treatment Market, by Treatment (Drug Type and Surgery), and by Geography - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028

  • To Be Published : Nov 2024
  • Code : CMI1536
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Market Challenges And Opportunities

Idiopathic trigeminal neuralgia, for which cause is unknown, is mostly treated with a single anticonvulsant medication such as carbamazepine. Carbamazepine, oxcarbazepine, gabapentin, lamotrigine or baclofen are some drugs used in treatment of TN. Carbamazepine often works well for trigeminal neuralgia and can ease symptoms of TN within 1-2 days. Its dose varies from patient to patient. Other medicines that ease nerve impulses can be used in combination of two drugs if one alone does not help. However, these medicines can cause various side effects such as amnesia, nausea, drowsiness, dizziness, and unsteadiness. Moreover, these drugs lose their effectiveness with time, requiring greater number of medications or higher doses taken together. Some patients experience side effects serious enough to discontinue the medication. Furthermore, some issues about diagnosis, surgical and pharmacological treatment of TN are unsettled. Major issues to address in the management of patients with TN include persistent side effects from medication, continued delays in diagnosis, and a lack of psychological support. All these factors are expected to hinder growth of the market during the forecast period. However, the European Federation of Neurological Societies and the American Academy of Neurology launched a combined task force to prepare general guidelines for the management of trigeminal neuralgia.

Market Dynamics

Increasing number of geriatric population is expected to drive growth of the trigeminal neuralgia treatment market worldwide as elderly people are more prone to get affected. Trigeminal neuralgia majorly affects people with age of 50 or more. It can occur at any age, including infancy. Young adults suffering from multiple sclerosis have high risk of developing TN. According to national Institute of Neurological Disorders and Stroke (NINDS), the number of new cases is around 12 per 100,000 each year. The condition is more common among women than in men. In young individuals, the cause is mostly idiopathic, but as compared to elderly, adult cases are mostly caused due to central nervous system damage similar to individuals with multiple sclerosis. The condition is extremely rare in children. However, various side effects such as amnesia, nausea, drowsiness, dizziness, and unsteadiness caused due to medications can negatively impact growth of the market. Furthermore, these drugs lose their efficacy over time.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.